- Home
- BATL vs SCNX Comparison
BATL vs SCNX Comparison
Compare BATL & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- SCNX
- Stock Information
- Founded
- BATL 1987
- SCNX 2010
- Country
- BATL United States
- SCNX United States
- Employees
- BATL N/A
- SCNX N/A
- Industry
- BATL Oil & Gas Production
- SCNX Other Pharmaceuticals
- Sector
- BATL Energy
- SCNX Health Care
- Exchange
- BATL Nasdaq
- SCNX Nasdaq
- Market Cap
- BATL 20.6M
- SCNX 21.2M
- IPO Year
- BATL N/A
- SCNX 2020
- Fundamental
- Price
- BATL $1.35
- SCNX $1.99
- Analyst Decision
- BATL
- SCNX
- Analyst Count
- BATL 0
- SCNX 0
- Target Price
- BATL N/A
- SCNX N/A
- AVG Volume (30 Days)
- BATL 113.7K
- SCNX 260.0K
- Earning Date
- BATL 08-13-2025
- SCNX 08-10-2025
- Dividend Yield
- BATL N/A
- SCNX N/A
- EPS Growth
- BATL N/A
- SCNX N/A
- EPS
- BATL N/A
- SCNX N/A
- Revenue
- BATL $191,498,000.00
- SCNX $146,901.00
- Revenue This Year
- BATL N/A
- SCNX N/A
- Revenue Next Year
- BATL N/A
- SCNX N/A
- P/E Ratio
- BATL N/A
- SCNX N/A
- Revenue Growth
- BATL N/A
- SCNX N/A
- 52 Week Low
- BATL $1.05
- SCNX $0.69
- 52 Week High
- BATL $6.89
- SCNX $14.84
- Technical
- Relative Strength Index (RSI)
- BATL 45.53
- SCNX N/A
- Support Level
- BATL $1.31
- SCNX N/A
- Resistance Level
- BATL $1.40
- SCNX N/A
- Average True Range (ATR)
- BATL 0.09
- SCNX 0.00
- MACD
- BATL 0.00
- SCNX 0.00
- Stochastic Oscillator
- BATL 63.64
- SCNX 0.00
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.